New Framework Evaluates Genomic Therapies for Patients
The proposed criteria weigh the high cost of permanent genetic edits against the efficacy of reversible clinical treatments.
Updated on Oct. 20, 2026 in Life Sciences
Live Poll
Would you choose a permanent genetic treatment over a traditional, reversible medication for a chronic condition?
Cardiologists at Michigan Medicine have proposed a new evaluation framework for determining the clinical justification of using genomic therapies to treat common, non-rare diseases. The researchers published five criteria to guide the medical community in weighing the high cost and permanence of these interventions against existing, reversible treatments.
Why it matters
As genomic medicine shifts from treating rare disorders to addressing common conditions, clinicians face the challenge of justifying high-cost, permanent interventions. This framework provides a standardized approach to assessing long-term risks when effective, non-permanent alternatives are available.
Current therapies often use AAV vectors—modified harmless viruses used as delivery vehicles—that frequently prevent patients from receiving a second dose. With list prices exceeding $1 million per patient, the permanence of these edits poses a significant medical and economic hurdle compared to reversible therapies.
The players
Eric D. Smith
A researcher at Michigan Medicine focused on the clinical implications of genomic medicine and cardiovascular health.
Venkatesh L. Murthy
A cardiologist at Michigan Medicine researching the intersection of advanced genomic therapies and internal medicine.
The details
Genomic therapies function by supplying a functional gene copy, silencing a harmful gene, or editing specific DNA sequences. Because these interventions target somatic cells—non-reproductive cells in the body—they do not affect future generations, but they are difficult to stop or adjust once deployed. The authors argue that current clinical trials are often too small and brief to detect rare complications, necessitating the implementation of independent, standardized safety monitoring systems.
Timeline
October 20, 2026: Perspective published in JAMA Internal Medicine.
The Tech Race
This proposal marks a pivot point as the industry moves from rare disease applications to high-volume cardiovascular conditions. It challenges existing research programs to prove that permanent gene-editing techniques can offer better durability than established, reversible lipid-lowering treatments.
This framework serves as a guide for clinicians and health systems, not individual patients, to evaluate which therapies merit high-cost investment. It signals that long-term safety monitoring systems for permanent genetic edits will become a key requirement for future clinical adoption.
The takeaway
Clinicians must balance the promise of one-time genetic fixes against the limitations of current viral delivery methods that preclude repeat dosing. Watch for the outcomes of ongoing research into single-treatment LDL reduction to see if the therapeutic benefits justify the $1 million-plus list price.
Further reading
For broader analysis on emerging genomic technologies, see our latest coverage in Life Sciences.
More information
Read the complete JAMA Internal Medicine perspective article for a full breakdown of the proposed framework.
Source note: This article includes information reported by News-Medical.
Live Poll
Would you choose a permanent genetic treatment over a traditional, reversible medication for a chronic condition?
